Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zynex, Inc. (ZYXI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Zynex is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management and rehabilitation, along with non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. Its filings offer detailed insight into this business focus, its financial condition, and its capital structure.
For ZYXI, annual reports on Form 10-K and quarterly reports on Form 10-Q describe revenue from devices and supplies, operating expenses, impairment charges, and risk factors. In 2025, the company also filed a Form 12b-25 explaining a delay in filing its third-quarter Form 10-Q and indicating that it expected to disclose substantial doubt about its ability to continue as a going concern, citing limited cash resources and the impact of payer-related issues.
Current reports on Form 8-K are especially important for understanding Zynex’s recent developments. These filings include disclosures about leadership changes, strategic initiatives, impairment charges at Zynex Monitoring Solutions, and, critically, the company’s voluntary Chapter 11 filings in the United States Bankruptcy Court for the Southern District of Texas. Related 8-Ks describe a restructuring support agreement with holders of its 5.00% Convertible Senior Notes due 2026, details of a debtor-in-possession financing facility, and Nasdaq’s determination to delist Zynex’s common stock as a result of the Chapter 11 cases.
Stock Titan’s platform surfaces these filings in real time as they are posted to EDGAR and pairs them with AI-powered summaries that explain key points in clear language. Users can quickly see what each 8-K addresses, how a 10-K or 10-Q discusses revenue trends, impairment charges, or going-concern language, and where documents reference restructuring milestones and listing status. The filings page also helps users locate information related to Zynex’s convertible notes, debtor-in-possession obligations, and other material agreements disclosed in its reports.
For those analyzing ZYXI, this page offers a structured way to review Zynex’s regulatory history, from its medical device business description to its Chapter 11 restructuring steps and Nasdaq delisting process, with AI-generated highlights to reduce the time needed to interpret complex filings.
Zynex Inc. director Barry D. Michaels reported a disposition of 80,001 shares of common stock back to the company, leaving him with zero shares. The transaction was recorded at a price of $0.00 per share and is classified as a disposition to the issuer.
According to the confirmed Chapter 11 reorganization plan, all outstanding Zynex common shares, stock awards, options, warrants, and related rights were cancelled for no consideration when the plan became effective on March 26, 2026, resulting in no recovery for existing equity holders.
Zynex Inc director Joshua R. Disbrow reported the cancellation of his equity holdings following the company’s Chapter 11 reorganization. On March 26, 2026, a total of 12,499 shares of restricted common stock and 89,501 shares of common stock were disposed of back to the issuer for no consideration, leaving zero shares reported as held.
This followed confirmation of Zynex’s Third Amended Chapter 11 Plan by the U.S. Bankruptcy Court for the Southern District of Texas on March 19, 2026, under which all outstanding common shares, equity awards, options, warrants and related rights were cancelled with no recovery under the plan.
Zynex Inc director Michael D. Cress reported disposing of all his common stock holdings back to the company as part of its Chapter 11 restructuring. The filing shows issuer dispositions of 12,499 shares of restricted common stock and 82,501 shares of common stock, leaving him with zero shares.
According to the confirmed reorganization plan, all outstanding Zynex common shares, equity awards, options, warrants and related rights were cancelled for no consideration when the plan became effective on March 26, 2026. Existing shareholders received no recovery under this court-approved plan.
Zynex, Inc. has emerged from Chapter 11 protection after a court confirmed reorganization plan became effective on March 26, 2026. As part of the plan, all previously issued equity, including existing common stock and equity awards, was cancelled and extinguished, and 1,000 new common shares were issued to Altivera Medical Holdings LLC, which now owns 100% of the company.
The company entered a new $10.0 million senior secured term loan maturing in 2034, which will convert into common stock once specified payments under a non-prosecution agreement are completed or at maturity. Zynex’s prior $22.3 million DIP facility and $60.0 million convertible notes were discharged. Amended articles now authorize up to 1,000,000 common shares, and new bylaws reset shareholder voting and governance procedures alongside board changes at both the sponsor and company level.
Zynex, Inc. reports that a U.S. bankruptcy court has entered a confirmation order approving its Chapter 11 reorganization plan and disclosure statement. Once conditions are met and the plan becomes effective, all existing equity interests, including the current 30,781,021 common shares, will be cancelled, released and extinguished. Approximately 1,000 new common shares will be issued to an entity owned by the DIP lenders as the plan sponsor, alongside $10 million of takeback debt. The company cautions that trading in its securities is highly speculative and expects existing equity holders to experience a significant loss on their investment if the restructuring transactions are implemented.
Zynex, Inc. reported that the U.S. Securities and Exchange Commission has concluded its investigation and, based on information available, does not intend to recommend an enforcement action against the company. This investigation had been previously disclosed.
The company also reminds investors that its common stock was delisted from Nasdaq following the commencement of voluntary Chapter 11 cases and now trades on the Pink Limited Market under the symbol ZYXIQ. Zynex cautions that trading in its securities during the Chapter 11 process is highly speculative, as the restructuring is expected to cause equity holders to experience a significant loss and the common stock is likely to be cancelled.